{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:01:27Z","timestamp":1790834487752,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT) indicates a poor prognosis. This study aims to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with hepatic arterial infusion chemotherapy (HAIC), apatinib, and camrelizumab in patients with uHCC accompanied by PVTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included patients with uHCC and PVTT who were treated at five tertiary medical centers in China between December 2021 and April 2025. Propensity score matching (PSM) was performed to minimize potential confounding bias. Treatment efficacy was assessed by objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). The primary endpoints were PFS and OS, whereas secondary endpoints included ORR and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 222 patients who met the eligibility criteria, 105 received TACE-HAIC combined with apatinib and camrelizumab (THAC group), and 117 received TACE combined with apatinib and camrelizumab (TAC group). After PSM, 86 matched patients were included in each group, and baseline characteristics were well balanced between the two groups. The THAC group achieved significantly higher intrahepatic tumor ORR (70.9% vs. 47.7%, P\u00a0=\u00a00.002) and DCR (94.2% vs. 79.1%, P\u00a0=\u00a00.004) than the TAC group. Similarly, for PVTT, the THAC group demonstrated significantly higher ORR (61.6% vs. 41.9%, P\u00a0=\u00a00.009) and DCR (90.7% vs. 74.4%, P\u00a0=\u00a00.005). The median PFS was significantly longer in the THAC group than in the TAC group (12 months vs. 7 months; HR\u00a0=\u00a00.287; 95%CI: 0.204\u20130.403; P&amp;lt;0.001). Likewise, the median OS was significantly prolonged in the THAC group (24 months vs. 16 months; HR\u00a0=\u00a00.198; 95%CI: 0.135\u20130.291; P&amp;lt;0.001). The incidence of adverse events did not differ significantly between the two groups (P&amp;gt;0.05). All adverse events were manageable, and no grade 5 adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with uHCC accompanied by PVTT, the THAC regimen was associated with superior survival outcomes compared with the TAC regimen while maintaining an acceptable safety profile. These findings suggest that THAC may represent a feasible and effective therapeutic option for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1917667","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:42:00Z","timestamp":1790833320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["TACE\u2013HAIC combined with apatinib and camrelizumab for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuexian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Interventional Medicine, The First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangbo","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine, The First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine, The First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine, The Second Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qikun","family":"Guo","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerou","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The First Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Qujing Second People\u2019s Hospital","place":["Qujing, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Vascular and Interventional Radiology, Jingmen People\u2019s Hospital, Jingchu University of Technology Affiliated Jingmen People\u2019s Hospital","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Vascular and Interventional Radiology, Jingmen People\u2019s Hospital, Jingchu University of Technology Affiliated Jingmen People\u2019s Hospital","place":["Jingmen, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine, The First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004131","article-title":"Efficacy and safety of TACE plus lenvatinib with PD-1 inhibitor for unresectable huge hepatocellular carcinoma: a multicenter retrospective cohort study","author":"Liang","year":"2025","journal-title":"Int J Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S339379","article-title":"Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma","volume":"8","author":"Huang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S567414","article-title":"TACE-HAIC plus targeted therapy and immunotherapy for HCC with tumor thrombus and arteriovenous fistula","volume":"12","author":"Liu","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6302","article-title":"A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001819","article-title":"Lenvatinib plus drug-eluting bead transarterial chemoembolization with\/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study","volume":"110","author":"Cai","year":"2024","journal-title":"Int J Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.042","article-title":"Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study","volume":"45","author":"Xiang","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000523997","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Liver Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1742116","article-title":"Hepatic arterial infusion chemotherapy combined with apatinib plus camrelizumab for advanced hepatocellular carcinoma with type Vp4 portal vein tumor thrombosis: a multicenter propensity score-matching analysis","volume":"17","author":"Wu","year":"2026","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.21037\/hbsn-2025-115","article-title":"Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2025","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15010","article-title":"Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis","volume":"35","author":"Liu","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1344798","article-title":"Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis","volume":"14","author":"Leung","year":"2024","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1038\/s41467-024-52700-z","article-title":"Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S286169","article-title":"Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study","volume":"13","author":"Yuan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1280837","article-title":"Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study","volume":"14","author":"Lu","year":"2024","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669856","article-title":"TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1779170","article-title":"DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"17","author":"Ma","year":"2026","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S537950","article-title":"TACE-HAIC versus TACE as initial regional therapy for unresectable huge hepatocellular carcinoma (>10 cm): a propensity score-matched study","volume":"12","author":"Liu","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1615506","article-title":"Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112711","article-title":"Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: a multi-center cohort study","volume":"139","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.749083","article-title":"Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: a review","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102022","article-title":"Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma","volume":"46","author":"Li","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31840","article-title":"Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors","volume":"74","author":"Cheu","year":"2021","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10519-8","article-title":"Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study","volume":"17","author":"Duan","year":"2023","journal-title":"Hepatol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01796","article-title":"Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial","volume":"44","author":"Zhu","year":"2026","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664756","article-title":"TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden-a propensity-score matching comparative study","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112492","article-title":"Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma","volume":"137","author":"Pang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:42:00Z","timestamp":1790833320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1917667"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1917667","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1917667"}}